**
A groundbreaking study has revealed that semaglutide, the active ingredient in popular weight-loss and diabetes medications like Wegovy and Ozempic, could be manufactured for a mere $3 (£2.35) per month. This revelation carries the potential to revolutionise treatment accessibility for millions suffering from obesity and diabetes, particularly in lower-income countries where healthcare resources are scant. The World Health Organization (WHO) had previously classified semaglutide as an essential medicine, but exorbitant prices have hindered its widespread use.
A Global Health Crisis
Obesity poses a dire threat worldwide, with over a billion individuals affected—a figure that continues to rise, especially in developing nations adopting Western dietary habits and increasingly sedentary lifestyles. The alarming trend has not gone unnoticed. In September of last year, the WHO categorised semaglutide as a crucial medicine, yet stakeholders warned that prohibitive costs were stifling access to this vital treatment.
With fresh research now suggesting that semaglutide could be produced at a fraction of its current retail price, the door may soon open for a significant change. The study, which has yet to undergo peer review, proposes that the injectable version of the drug could be manufactured for just $3 a month. An oral formulation is projected to cost around $16 monthly.
Patent Expirations and Market Opportunities
Significantly, the research highlights that key patents for semaglutide are set to expire in ten countries this year, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, beginning on March 21. This development paves the way for generic alternatives to enter the market. Furthermore, the researchers identified an additional 150 nations where patents had not been filed, primarily across Africa. Altogether, these regions account for a staggering 69% of individuals with type 2 diabetes and 84% of those classified as obese.
Dr. Andrew Hill from Liverpool University, one of the study’s authors, stated, “These low prices open the door to worldwide access to an essential medicine.” His optimism is echoed by Prof. François Venter from Witwatersrand University, who remarked that similar strategies have successfully improved access to treatments for diseases such as HIV, tuberculosis, and malaria in low- and middle-income countries. Venter envisions a similar success story for semaglutide.
The Bigger Picture: Addressing Structural Issues
Despite the promise of affordable treatment, researchers caution against viewing lower drug costs as a panacea for the obesity epidemic. The underlying structural issues, such as food insecurity, poverty, and urbanisation, must also be addressed. Dr. Nomathemba Chandiwana, chief scientific officer at South Africa’s Desmond Tutu Health Foundation, emphasised that while cheaper access to semaglutide could be a game changer for many in low-income nations, it is crucial that health systems integrate these drugs responsibly within a broader framework of obesity and diabetes care.
Chandiwana pointed out that approximately 27% of adults globally meet the criteria for treatments like semaglutide, with a significant proportion residing in low- and middle-income countries where access remains severely limited. She stressed the importance of coordinated policies and procurement strategies to maximise the benefits of this new research.
The Current Landscape of Diabetes and Obesity
The statistics surrounding diabetes are staggering. From 200 million cases in 1990, the number skyrocketed to 830 million by 2022, with the sharpest increases observed in less affluent regions. Obesity is linked to numerous health complications, including heart disease, stroke, diabetes, and even cancer, resulting in approximately 3.7 million deaths annually attributed to excessive weight.
Semaglutide first received approval from US regulators in 2017, yet patients in the US pay around $200 per month, while those in the UK face costs of about £120 monthly. Patents in the UK and across Europe remain in effect for another five years, creating a window of opportunity for generics in regions where patents are expiring.
Why it Matters
The implications of this research are profound. If semaglutide can indeed be manufactured at such a low cost, it could usher in a new era of treatment accessibility for those grappling with obesity and diabetes in resource-poor settings. This development could not only save lives but also alleviate the strain on healthcare systems already burdened by rising chronic disease rates. As the world grapples with the dual crises of obesity and diabetes, ensuring equitable access to effective treatments will be crucial in the fight against these public health challenges.
